Physician profile
Marlene Ann Bednar
NPI 1821035015
$627.98
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $12.09 · 2021: $190.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $335.07 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $78.24 | 2019 | |
| Amgen INC. | $56.51 | 2019 | |
| Supernus Pharmaceuticals, INC. | $32.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.43 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $27.36 | 2021 | |
| Eisai INC. | $24.65 | 2019 | |
| Emd Serono, INC. | $17.19 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.06 | 2021 | |
| Lilly USA, LLC | $12.09 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Bednar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.